利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.03 秒)

    NOVEL ADENINE COMPOUND
    3.
    发明公开
    NOVEL ADENINE COMPOUND 审中-公开
    新的腺嘌呤化合物

    公开(公告)号：EP1939200A1

    公开(公告)日：2008-07-02

    申请号：EP06798242.1

    申请日：2006-09-22

    申请人： Dainippon Sumitomo Pharma Co., Ltd. ,  AstraZeneca AB

    发明人： MILLICHIP, Ian ,  MCINALLY, Thomas ,  BONNERT, Roger

    IPC分类号： C07D473/18 ,  A61K31/522 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P27/02 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/34

    CPC分类号： C07D473/18

    摘要： A novel adenine compound represented by the formula (1):

    wherein Z represents (un)substituted alkylene, a single bond, etc.; R 1 represents an (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl group; R 2 represents hydrogen or (un)substituted alkyl; R 3 , R 4 and R 5 each independently represents an (un)substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl group, provided that R 3 and R 5 may be bonded to each other to form a 3- to 7-membered, saturated carbocycle or heterocycle in cooperation with the adjacent carbon atom; and X represents oxygen, sulfur, SO 2 , NR 6 (R 6 represents hydrogen or alkyl), or a single bond, or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.

    摘要翻译： 由式（1）表示的新型腺嘌呤化合物：其中Z代表（未）取代的亚烷基，单键等; R1代表（未）取代的烷基，烯基，炔基，环烷基，芳基或杂芳基; R2代表氢或（未）取代的烷基; R 3，R 4和R 5各自独立地表示（未）取代的烷基，烯基，炔基，芳基或杂芳基，条件是R 3和R 5可以彼此键合以形成3-至7-元饱和碳环或杂环 与相邻碳原子合作; X代表氧，硫，SO 2，NR 6（R 6代表氢或烷基）或单键，或该化合物的药学上可接受的盐。 该化合物和盐可用作药物。

    NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES
    5.
    发明公开
    NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES 有权
    苯基高分子量胺衍生物的新用途

    公开(公告)号：EP1263718A1

    公开(公告)日：2002-12-11

    申请号：EP01904777.8

    申请日：2001-02-20

    申请人： AstraZeneca AB

    发明人： CHESHIRE, David ,  CONNOLLY, Stephen ,  COX, David ,  MILLICHIP, Ian

    IPC分类号： C07C323/31 ,  C07C317/32 ,  C07C255/50 ,  C07C217/54 ,  C07C211/49 ,  C07D295/04 ,  A61K31/00 ,  A61P29/00 ,  A61P43/00

    CPC分类号： C07D295/125 ,  A61K31/137 ,  A61K31/277 ,  A61K31/421 ,  A61K31/426 ,  A61K31/5375 ,  A61K31/695 ,  C07C211/48 ,  C07C255/58 ,  C07C317/28 ,  C07C323/29 ,  C07C323/62

    摘要： There is disclosed the use of a compound of formula (I), wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prohylaxis of inflammatory disease.

    摘要翻译： 公开了其中R 1，R 2，X，Y，V，W和Z如说明书中所定义的式（I）化合物及其药学上可接受的盐，对映异构体或外消旋物在制备 药物，用于治疗或预防其中抑制一氧化氮合酶活性有益的疾病或病症。 公开了式（Ia）的某些新型化合物及其药学上可接受的盐，以及其对映体和外消旋体; 以及它们的制备方法，含有它们的组合物以及它们在治疗中的用途。 式（I）和（Ia）的化合物是酶一氧化氮合酶的抑制剂，因此特别可用于治疗或预防炎性疾病。